posted
DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that research to develop commercial grade PT-401, a more powerful form of the anemia drug Erythropoietin (EPO), is proceeding on schedule with the manufacturing of PT-401 in mammalian cells being shown to be very efficient. Erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past 5 years. MarketWire. Is this the news you mean?
-------------------- If ignorance is bliss, why aren't more people happy?
IP: Logged |
posted
Jim- Any idea when this comes off SHO? Boy level 2 ask is so weak right now it would not take much pressure at all to shoot up to .03. I think mm's would stand aside and let her go if volume came in. Any idea what average volume (3month) is for this?
IP: Logged |
posted
Jim- You seem to know alot about MM's. What would make the MM's decide to cover their shorts? IS the decision strictly based on the number of shares they own?
posted
They tried to swing between 0.0238 to 0.0265 and shake out more shares. In the mean time if enough traders step in to get hold of some of the shares, the MMs will be forced to cover their short positions. If the volume continue to build up, the Mms will lose control and let her go. The chart and volume will attract more traders, which will, in turn, build up volume. This interaction will result in a big run. Just check the volume every day and wait for it to happen.
IP: Logged |
posted
Thaks for info Jim... I will answer my other question.... 3 month average volume is 6 million sometimes it makes sense to get off my duff and DD myself!
posted
DNAG: the pps has been pulled-down by a factor of 50.0 -- a huge rebounce is expected. The MMs' collecting phase is almost completed. They will gradually raise the pps to unload their inventory. Watch it.
posted
It would appear that OLMP is the big bully again today holding this down. Alot of buys went through at .0259 and he wouldn't budge. That was the turning point of this day.
6) BC-LOH – Breast Cancer (DNAPrint/Moffitt) * R/D 2003… Diagnostic Phase I - 2004/08…FDA-PMA 3Q08…Launch 2009 * Market Potential - $400 Million Dollars
7) Xeliri/Xelox – Colon Cancer (DNAPrint/Moffitt) * R/D 2003… Diagnostic Phase I - 2005/08…FDA-PMA 4Q08…Launch 2009 * Market Potential - $200 Million Dollars
8) Diabetes – Pre-Diabetes and Diabetic Complications * R/D 2005... Diagnostic Phase I – 1Q06… FDA-PMA 1Q09…Launch 2010 * DNAPrint licensed diabetes diagnostics test from Harvard Medical School – Jan 26, 2006 * Market Potential - $5 Billion Dollars * New - Feb 14, 2006 - DNAPrint Pharmaceuticals Retains DOCRO for Development of Immunoassay to Better Detect Diabetic Vascular Complications. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint's recently in-licensed intellectual property relating to glycated CD59. "DOCRO is a leading CRO specializing in the commercialization of diagnostic technologies," commented Dr. Hector J. Gomez, MD, PhD…"DOCRO's proven formula for success has resulted in an unparalleled track record at the FDA with over seventy consecutive successful FDA submissions."
Theranostics Products – Drug and Drug Test Combinations
9) PT-201 – Opthalmic Allergies * Phase II – 2Q06…FDA-NDA 4Q07…Launch 2008 * Market Potential - $50 Million Dollars
10) PT-202 – Nasal Allergies * Phase I – 2Q06…FDA-NDA 4Q07…Launch 2008 * Market Potential - $50 Million Dollars
11) PT-301 – Atopic Dermatitis * Phase I – 2Q06…FDA- NDA 2Q08…Launch 2009 * Market Potential - $600 Million Dollars
12) PT-401 - Super EPO Anemia Drug – Renal Failure * License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA-NDA 2009…Launch 2010 * Market Potential - $2.5 Billion Dollars – Revised 3/14/06 - $11 Billion Dollars * DNAPrint exclusive worldwide license to develop a Super EPO anemia drug for renal failure * Consulting contract with Super EPO inventor/patent-holder to help DNAPrint develop Super EPO drug * Contract for CRO to manufacture Super EPO drug for pre-clinical testing, ready Fall 2005 (completed) * Sept 2005 – Super EPO drug begins pre-clinical testing. Production schedule remains on track * TWST – “We expect to file a New Drug Application (NDA) by 2009 and a product launch somewhere around 2010.” * New – Mar 14, 2006 – DNAPrint™ Genomics Pharmaceuticals Division Announces That Research on Development of Super EPO Drug for Anemia Market Shows Promising Early Results
13) PT-501 – ADHD - Methylphenidate – Ritalin-like Compounds * License Oct 2005….Pre-clinical 2005…FDA-NDA 2009…Launch 2010 * Market Potential - $4.6 Billion Dollars * Oct 25, 2005 -- DNAPrint genomics, Inc. today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine….Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, (Decision Resources, Inc)…. *Dr. Froimowitz and DNAPrint genomics are working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse. * TWST - Drug addiction compound has actually been selected by the National Institute of Drug Abuse (NIDA) for further study. * New – Mar 3, 2006 - DNAPrint announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. “In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
14) PT-502 – Drug Addiction - Methylphenidate – Ritalin-like Compounds * License Oct 2005…. Pre-clinical 2005…FDA-NDA 2010…Launch 2011 * Market Potential - $500 Million Dollars
20) BF 200 ALA – Kondyloma – for epidermotropic human papillomavirus (HPV)…in Clinical Phase II…Market 2009
21) BF 200 ALA – VIN III – for vulvar intraepithelial neoplasia …in Clinical Phase II…Market 2009
22) 5-HT2B receptor antagonist - for migraine prophylaxis - in Preclinical 2005…Market ?
Other DNAPrint Studies
23) Immune System Deficiencies and Suppressants - Sirolimus, Tacrolimus, Mycophenolate * R/D 2001…NYU?…. Fall 2005 - Elipsis Biotherapeutics – Crohn’s Disease and other immune system disorders
24) Acute Lymphocyte Leukemia (ALL) * R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?…..
25) Cervical Cancer and Environmental Tobacco Smoke * FAMRI Grant Feb 2003….2 year grant….Publication 2006?....
PARTNERS
* Forensics and Consumer Genealogy - Lynn Peavey, Orchid Biosciences, and ReliaGene Technologies * Forensics – DNAPrint working with defense industry consultant, Defense Life Sciences, towards defense and homeland security applications…Aug 2005
MERGERS, ACQUISITIONS, and SUBSIDIARIES
* DNAPrint Pharmaceuticals Subsidiary – DNAPrint Genomics forms wholly owned pharmaceutical subsidiary focused on personalized medicine, DNAPrint Pharmaceuticals…Oct 12, 2005 * "We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products." Data Monitor and the Pharmaceutical Manufacturer's Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year.
* DNAPrint ACQUISITION – Trace Genetics…Acquired Jun 2005 * Trace Genetics – diagnostics specialists in genetic identity DNA analysis, with expertise in genetic genealogy, forensics, molecular diagnostics and population genetics * Trace Genetics will do product testing, production, and sales for forensics and consumer genealogy while DNAPrint continues core drug discovery research and clinical trials for DNAPrint’s growing drug pipeline.
* DNAPrint ACQUISTION…Biofrontera AG…July 13, 2005 * DNAPrint Genomics Acquires 18% Interest In Biofrontera AG, a Small German Pharmaceutical Company * Biofrontera has proprietary programs for gene expression analysis and has 3 drugs already in their pipeline * Biofrontera just acquired a new drug (Sept 2005) and now has 4 drugs in their pipeline * Biofrontera milestone: Biofrontera stated intentions to do an IPO stock offering in Europe. * Sept 2005 – Biofrontera completes bond funding for $20 million euro. Biofrontera’s new IPO stock offering is on track within 9 months * Sept 2005 – Biofrontera acquires new drug for Atopic Dermatitis for it’s drug pipeline
* DNAPrint ACQUISITION – Kenna Technologies, Inc…Acquired Oct 25, 2005 Kenna Technologies, Inc., expertise in computational biology. Kenna is an in-silico drug discovery company developing proprietary biological simulations that will improve and accelerate drug discovery and development. Kenna’s platform provides a new rationale for selecting drug targets, evaluating the activity of candidate compounds, and planning clinical trials for promising drug compounds.
* DNAPrint ACQUISITION – Elipsis Biotherapeutic Corporation…Acquired Dec 22, 2005 SARASOTA, Fla., Dec. 22, 2005 -- DNAPrint Genomics, Inc. today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael's Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn's disease) including last year's publications of the discovery of a gene for Crohn's disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders. * New – Feb 21, 2006 - Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services For Record Quarter Of Revenues
* New - DNAPrint - Research Sponsorship Agreement with Mass.College of Pharmacy and Health Sciences - 8-K Jan 31, 2006 On January 31, 2006, the Registrant entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for sponsored research in connection with the synthesis and testing of certain (Ritalin) compounds as possible human medications for drug abuse, attention deficit hyperactivity disorder, and depression. The research will be conducted under the supervision of Dr. Mark Froimowitz. The Registrant had previously licensed exclusive rights to the compounds from Dr. Froimowitz on October 19, 2005 under an Exclusive Licensing Agreement. The sponsored research payments total $300,000 and will be paid in monthly installments of $25,000 over one (1) year. ---------
All drugs, projects, acquisitions, and other data listed in this DNAPrint pipeline may or may not be inclusive of all possible drugs, projects or acquisitions that DNAPrint may presently be involved in. Milestone dates are subject to change by DNAPrint Genomics.
** Note: All above information on DNAPrint's research, acquisitions, and drug products pipeline are all documented from DNAPrint’s newsletters, PR's, Analyst Reports, and SEC filings.
Of course, Do Your Own DD….and make your own best informed investment decisions.
IP: Logged |
posted
MAC- Another solid start to day and looks like a pretty good shot to at least close at .026. 3mm's on bid at .026. Not much resistence left until .03. I would think we could start seeing some .03 buys early next week. Volume is a little light but not too bad. It keeps building a little more momentum each day.
We have been sitting pretty with our 6% gains each day. I'll take it, that's for sure.
But I think the top is wound nice and tight and is getting ready to be cut loose. Friday's trading may be light, but if not look out. 03 is just around the corner!
IP: Logged |
posted
JIMSC, I think you are right. Tommorrow may be the start of a big run for DNAG. If it is not it will be soon. Buying pressure too strong.
IP: Logged |
posted
DNAG: I don't mind if the MMs hold her longer, as long as she gets to jump up 6% a day. The chart looks so perfect. Don't you think so?
IP: Logged |
posted
Jim- Awesome Day yesterday. Looks like the MM's are lining up to keep it under .003. But 1,000,000 volume already. We will need a huge volume day to break .003
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
